Beigene, LTD Form 4 insider transactions

Lai Wang, Global Head of R&D at BeiGene, reports the acquisition of ordinary shares and share options in a recent Form 4 filing with the SEC.

SVP, General Counsel of BeiGene, Chan Henry Lee, reports acquiring shares and share options while disposing of existing shares.

Director Margaret Dugan reports acquiring shares and options in BeiGene, Ltd. related to restricted share units and share options.

Director Olivier Brandicourt acquired shares and options in BeiGene, Ltd. on June 5, 2024, according to a Form 4 filing.

Director Anthony C. Hooper reports acquisition of 16,341 ordinary shares and disposal of shares, along with the grant of share options.

John Oyler, CEO of BeiGene, Ltd., reports the acquisition of shares and a grant of share options, along with details of shares held indirectly through various trusts.

Director Donald W. Glazer reports acquisition of ordinary shares and share options in BeiGene, Ltd.

Director Alessandro Riva acquired 16,341 ordinary shares and options for 34,151 ordinary shares of BeiGene, Ltd.

Director Wang Xiaodong reports acquisition of shares and grant of share options in BeiGene, Ltd.

Director Corazon Sanders reports acquisition of BeiGene shares and options, signaling changes in beneficial ownership.

Julia Wang, CFO of BeiGene, reports acquiring shares and options, and disposing of shares, according to a recent SEC Form 4 filing.

Director Qingqing Yi reports acquisition and disposal of BeiGene shares and share options.

Baker Bros. Advisors LP and related entities report changes in beneficial ownership of BeiGene, Ltd. stock and options due to grants of restricted stock units and share options to employees serving as directors.

BeiGene's CEO, John Oyler, executed multiple sales of American Depositary Shares (ADS) between April 9 and April 11, 2024, under a pre-arranged Rule 10b5-1 trading plan.

BeiGene's CEO, John Oyler, executed sales of American Depositary Shares (ADS) on March 12th and 13th, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Donald W. Glazer reported gifting 82,020 ordinary shares of BeiGene, Ltd. on March 11, 2024.

Director Olivier Brandicourt acquired 27,794 share options in BeiGene, Ltd. on February 29, 2024, according to a Form 4 filing.

Julia Wang, CFO of BeiGene, Ltd., sold American Depositary Shares to satisfy tax withholding obligations related to vesting restricted share units.